Compare Bristol-Myers Squibb Co (BMY) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Bitdeer Technologies Group — how do they compare? Bristol-Myers Squibb Co trades at $63.84 (market cap $129.94B), while Bitdeer Technologies Group trades at $9.02 (market cap $2.36B). The key difference: Bristol-Myers Squibb Co is far larger — about 55.1× Bitdeer Technologies Group's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Bitdeer Technologies Group pays none. Which is the better fit depends on your goals.
| BMY | BTDR | |
|---|---|---|
Market Cap | $129.94B | $2.36B |
Sector | Health | Technology |
52-Week High | $65.89 | $25.90 |
52-Week Low | $42.60 | $7.28 |
Enterprise Value | $163.92B | $3.85B |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
BTDR trades at $9.30, up 6.96% today, but faces bearish technical signals with 13 of 13 moving averages signaling sell. The company reported four consecutive quarterly earnings misses, with Q2 2026 loss of $0.37 per share missing expectations. Despite negative profitability metrics (-28.14% net margin), analyst consensus remains strongly bullish with 82% buy ratings and $22.43 price target. Recent $4.7 billion AI data center deal provides long-term revenue visibility amid Bitcoin mining challenges.
The stock presents high-risk opportunity with significant analyst upside potential but faces execution risks in transitioning from Bitcoin dependency to AI infrastructure. Near-term pressure from negative cash flow and margin compression contrasts with long-term AI contract value. Investors must weigh strong institutional support against persistent profitability challenges and crypto market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
